A one-minute look back at the week of January 19, 2015, in managed care, including Marilyn Tavenner's departure from CMS and oncology drug pricing.
The top story in managed care this week was the news that Marilyn Tavenner would be resigning from her post as chief of CMS at the end of February. Andy Slavitt is slated to take over temporarily until Senate approves his appointment or another candidate is confirmed.
Although clinical trial results for Kite Pharma’s cancer immuno-therapy aren’t due until 2016, the company learned its lesson from last year’s price wars over Gilead’s hepatitis C treatment.
Lastly, we invite you to take a look at this month’s The American Journal of Managed Care as we kick off our 20th year of publication with a special commentary by co-editors-in-chief, A. Mark Fendrick, MD, and Michael E. Chernew, PhD.
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More